Kenneth Mann

Summary

Affiliation: University of Vermont
Country: USA

Publications

  1. pmc Tissue factor controversies
    Kenneth G Mann
    University of Vermont, Department of Biochemistry, Burlington, VT, corrected USA
    Thromb Res 129:S5-7. 2012
  2. pmc Anticoagulants and the propagation phase of thrombin generation
    Thomas Orfeo
    Department of Biochemistry, University of Vermont, Colchester, Vermont, United States of America
    PLoS ONE 6:e27852. 2011
  3. pmc Modeling of human factor Va inactivation by activated protein C
    MARIA CRISTINA BRAVO
    Cell and Molecular Biology Program, University of Vermont, 89 Beaumont Ave, Burlington, VT 05405, USA
    BMC Syst Biol 6:45. 2012
  4. pmc Rivaroxaban delivery and reversal at a venous flow rate
    Laura M Haynes
    Department of Biochemistry, University of Vermont College of Medicine, Colchester, VT 05446, USA
    Arterioscler Thromb Vasc Biol 32:2877-83. 2012
  5. ncbi request reprint Models of blood coagulation
    Kenneth G Mann
    Department of Biochemistry, 208 South Park Drive, Suite 2, University of Vermont, College of Medicine, Colchester, VT 05446, USA
    Blood Cells Mol Dis 36:108-17. 2006
  6. pmc Blood coagulation dynamics in haemostasis
    K G Mann
    University of Vermont, Department of Biochemistry, Burlington, VT, USA
    Hamostaseologie 29:7-16. 2009
  7. ncbi request reprint Adding the vessel wall to Virchow's triad
    K G Mann
    Department of Biochemistry, University of Vermont, Burlington, VT 05405, USA
    J Thromb Haemost 4:58-9. 2006
  8. ncbi request reprint The challenge of regulating anticoagulant drugs: focus on warfarin
    Kenneth G Mann
    Vermont College of Medicine, Department of Biochemistry, University of Vermont, Burlington, VT 05405, USA
    Am Heart J 149:S36-42. 2005
  9. ncbi request reprint Does the genotype predict the phenotype? Evaluations of the hemostatic proteome
    K G Mann
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT 05405, USA
    J Thromb Haemost 2:1727-34. 2004
  10. ncbi request reprint Thrombin: can't live without it; probably die from it
    Kenneth G Mann
    Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Chest 124:1S-3S. 2003

Research Grants

  1. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 1999
  2. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2004
  3. Symphony Multiplex Peptide Synthesizer w/ VISION Workstn
    Kenneth Mann; Fiscal Year: 2004
  4. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2005
  5. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2006
  6. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2007
  7. HEMOSTASIS AND THROMBOSIS PROGRAM FOR ACADEMIC TRAINEES
    Kenneth Mann; Fiscal Year: 2007
  8. Surface Dependent Reactions in Thrombosis and Thrombolysis
    Kenneth Mann; Fiscal Year: 2007
  9. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2003
  10. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2002

Collaborators

Detail Information

Publications84

  1. pmc Tissue factor controversies
    Kenneth G Mann
    University of Vermont, Department of Biochemistry, Burlington, VT, corrected USA
    Thromb Res 129:S5-7. 2012
    ..This presentation will review data on the architecture and functions of the tissue factor-factor VIIa complex and discuss the elements of the controversies associated with tissue factor presentation in both normal and pathologic milieu...
  2. pmc Anticoagulants and the propagation phase of thrombin generation
    Thomas Orfeo
    Department of Biochemistry, University of Vermont, Colchester, Vermont, United States of America
    PLoS ONE 6:e27852. 2011
    ..More generally, the study shows that computational modeling of the response of core elements of the coagulation proteome to a physiologically relevant tissue factor stimulus may improve the monitoring of a broad range of anticoagulants...
  3. pmc Modeling of human factor Va inactivation by activated protein C
    MARIA CRISTINA BRAVO
    Cell and Molecular Biology Program, University of Vermont, 89 Beaumont Ave, Burlington, VT 05405, USA
    BMC Syst Biol 6:45. 2012
    ..An empirically validated mathematical model of this process would be useful in advancing the predictive capacity of comprehensive models of coagulation...
  4. pmc Rivaroxaban delivery and reversal at a venous flow rate
    Laura M Haynes
    Department of Biochemistry, University of Vermont College of Medicine, Colchester, VT 05446, USA
    Arterioscler Thromb Vasc Biol 32:2877-83. 2012
    ....
  5. ncbi request reprint Models of blood coagulation
    Kenneth G Mann
    Department of Biochemistry, 208 South Park Drive, Suite 2, University of Vermont, College of Medicine, Colchester, VT 05446, USA
    Blood Cells Mol Dis 36:108-17. 2006
    ..Ideally, our results will provide descriptions which predict the behavior of the biological blood coagulation system under normal and pathologic conditions...
  6. pmc Blood coagulation dynamics in haemostasis
    K G Mann
    University of Vermont, Department of Biochemistry, Burlington, VT, USA
    Hamostaseologie 29:7-16. 2009
    ..Our systems have been utilized to examine the qualities of hypothetical and novel antihaemorrhagic and anticoagulation agents and in epidemiologic studies of venous and arterial thrombosis and haemorrhagic pathology...
  7. ncbi request reprint Adding the vessel wall to Virchow's triad
    K G Mann
    Department of Biochemistry, University of Vermont, Burlington, VT 05405, USA
    J Thromb Haemost 4:58-9. 2006
  8. ncbi request reprint The challenge of regulating anticoagulant drugs: focus on warfarin
    Kenneth G Mann
    Vermont College of Medicine, Department of Biochemistry, University of Vermont, Burlington, VT 05405, USA
    Am Heart J 149:S36-42. 2005
  9. ncbi request reprint Does the genotype predict the phenotype? Evaluations of the hemostatic proteome
    K G Mann
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT 05405, USA
    J Thromb Haemost 2:1727-34. 2004
    ..It is the intention of the authors to be provocative; encouraging further investigations to understand the clinical significance of the heterogeneity of the human hemostatic proteome...
  10. ncbi request reprint Thrombin: can't live without it; probably die from it
    Kenneth G Mann
    Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Chest 124:1S-3S. 2003
  11. pmc Taking the thrombin "fork"
    Kenneth G Mann
    University of Vermont, College of Medicine, 208 South Park Drive, Colchester, VT 05446, USA
    Arterioscler Thromb Vasc Biol 30:1293-9. 2010
    ..take it." My career is a consequence of chance interactions with great mentors and talented students and the opportunities provided by a succession of ground-breaking improvements in technology...
  12. ncbi request reprint Citrate anticoagulation and the dynamics of thrombin generation
    K G Mann
    Department of Biochemistry, University of Vermont, Colchester, VT 05446, USA
    J Thromb Haemost 5:2055-61. 2007
    ..Anticoagulation of blood without chelation can be achieved by inhibition of the contact pathway by corn trypsin inhibitor (CTI)...
  13. ncbi request reprint Blood coagulation
    S Butenas
    University of Vermont, Department of Biochemistry, Burlington, VT 05405 0068, USA
    Biochemistry (Mosc) 67:3-12. 2002
    ..The majority of data accumulated in in vitro models and discussed in this review are in good agreement with the results of in vivo observations...
  14. pmc The plasma hemostatic proteome: thrombin generation in healthy individuals
    K Brummel-Ziedins
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT 05405, USA
    J Thromb Haemost 3:1472-81. 2005
    ..The range of plasma concentrations of hemostatic analytes in the population is wide. In this study these components of blood coagulation phenotype are integrated in an attempt to predict clinical risk...
  15. ncbi request reprint Oral anticoagulation thresholds
    K E Brummel
    Department of Biochemistry, Given Building, Health Science Complex University of Vermont, College of Medicine, Burlington, USA
    Circulation 104:2311-7. 2001
    ..Patients with similar INRs show significant individual variability in their tissue factor coagulation response, suggesting different risks to anticoagulation when confronted with underlying vascular anomalies...
  16. ncbi request reprint Antiplatelet agents in tissue factor-induced blood coagulation
    S Butenas
    Department of Biochemistry, College of Medicine, University of Vermont, Burlington 05405-0068, USA
    Blood 97:2314-22. 2001
    ....
  17. ncbi request reprint How factor VIIa works in hemophilia
    S Butenas
    Department of Biochemistry, University of Vermont, 89 Beaumont Avenue, Burlington, VT 05405 0068, USA
    J Thromb Haemost 1:1158-60. 2003
    ..FVIIa appears to function effectively and locally by the combined effect of TF expression and platelet accumulation at the site of a vascular lesion...
  18. ncbi request reprint Thrombin generation: phenotypic quantitation
    K E Brummel-Ziedins
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT 05405, USA
    J Thromb Haemost 2:281-8. 2004
    ..Overall, these data suggest that thrombin generated in whole blood exclusively by tissue factor stimulation can be used as an integrative phenotypic marker to determine an individual's response to a tissue factor challenge...
  19. ncbi request reprint Osteonectin in matrix remodeling. A plasminogen-osteonectin-collagen complex
    R J Kelm
    University of Vermont, Department of Biochemistry, College of Medicine, Burlington 05405
    J Biol Chem 269:30147-53. 1994
    ....
  20. pmc Mathematical and biological models of blood coagulation
    T Orfeo
    Department of Biochemistry, University of Vermont, Burlington, VT, USA
    J Thromb Haemost 3:2397-8. 2005
  21. ncbi request reprint The mechanism of inactivation of human factor V and human factor Va by activated protein C
    M Kalafatis
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington 05405 0068
    J Biol Chem 269:31869-80. 1994
    ..However, while this cleavage site is exposed on membrane-bound human factor V, cleavage at Arg506 on the heavy chain of factor Va appears necessary for complete exposure of the cleavage site at Arg306...
  22. ncbi request reprint Thrombin functions during tissue factor-induced blood coagulation
    Kathleen E Brummel
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT 05405, USA
    Blood 100:148-52. 2002
    ..6 +/- 0.6 minutes). These results illustrate that the initial activation of thrombin substrates occurs during the initiation phase at less than 2 nM thrombin (0.2%). Most thrombin (96%) is formed well after clotting occurs...
  23. ncbi request reprint Statins and blood coagulation
    Anetta Undas
    Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
    Arterioscler Thromb Vasc Biol 25:287-94. 2005
    ..Treatment with statins can lead to a significant downregulation of the blood coagulation cascade, most probably as a result of decreased tissue factor expression, which leads to reduced thrombin generation...
  24. ncbi request reprint Kinetics of human factor VII activation
    S Butenas
    Department of Biochemistry, University of Vermont, Burlington 05405, USA
    Biochemistry 35:1904-10. 1996
    ..These data allow us to conclude that the predominant physiological factor VII activator is, most likely, membrane-bound factor Xa...
  25. ncbi request reprint Factor VIIa replacement therapy in factor VII deficiency
    K Brummel Ziedins
    Department of Biochemistry, University of Vermont, Burlington, Vermont 05405, USA
    J Thromb Haemost 2:1735-44. 2004
    ..3-0.7 nmol L(-1)/equivalent dose: 0.8-1.8 micro g kg(-1)) is approximately 1/10 that currently used in treating FVII-deficient individuals and suggests that therapies should be altered relative to the concentration of the FVII zymogen...
  26. pmc Thrombin generation profiles in deep venous thrombosis
    K E Brummel-Ziedins
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT 05405, USA
    J Thromb Haemost 3:2497-505. 2005
    ..Reliable markers and methods to predict risk for thrombosis are essential to clinical management...
  27. pmc Potency and mass of factor VIII in FVIII products
    S Butenas
    Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
    Haemophilia 15:63-72. 2009
    ..Thus, the administration of an equal FVIII potency in units means the administration of different amounts of FVIII protein, which may partly explain apparent discrepancies in product performance...
  28. ncbi request reprint Increased tissue factor-initiated prothrombin activation as a result of the Arg506 --> Gln mutation in factor VLEIDEN
    C Van 't Veer
    Department of Biochemistry, University of Vermont, Burlington, Vermont 05405 0068, USA
    J Biol Chem 272:20721-9. 1997
    ..Altogether the data predict that TFPI levels in the lower range of normal values are a risk factor for thrombosis when combined with the Arg506 --> Gln mutation in factor VLEIDEN...
  29. pmc The nature of the stable blood clot procoagulant activities
    Thomas Orfeo
    Department of Biochemistry, University of Vermont, Colchester, VT 05446, USA
    J Biol Chem 283:9776-86. 2008
    ..e. hemophilias A and B, result in an impaired capacity to mount a resupply response; and 3) in normal hemostasis the intrinsic factor Xase function contributes to the durability of the resupply response...
  30. ncbi request reprint Blood coagulation at the site of microvascular injury in healthy and coumadin-treated subjects heterogenous for factor V Leiden mutation
    Anetta Undas
    Department of Medicine, Jagiellonian University School of Medicine, Crakow, Poland
    Thromb Haemost 98:1024-30. 2007
    ..Inactivation of FVa by the APC mechanism is attenuated significantly in carriers of FV Leiden but the magnitude of this effect is smaller than that observed in most purified systems...
  31. ncbi request reprint Structural requirements for expression of factor Va activity
    Michael Kalafatis
    Department of Chemistry, Cleveland State University, and The Lerner Research Institute, The Cleveland Clinic Foundation, Ohio, USA
    J Biol Chem 278:33550-61. 2003
    ....
  32. pmc The tissue factor requirement in blood coagulation
    Thomas Orfeo
    Department of Biochemistry, University of Vermont, Burlington, Vermont 05405, USA
    J Biol Chem 280:42887-96. 2005
    ..These observations support the hypothesis that the transient, localized expression of TF is sufficient to sustain a TF-independent procoagulant response as long as flow persists...
  33. ncbi request reprint Interchangeability of rotational elastographic instruments and reagents
    Maya Aleshnick
    From the Department of Biochemistry, University of Vermont, Colchester, Vermont
    J Trauma Acute Care Surg 76:107-13. 2014
    ..In this study, we perform a crossover analysis between the TEG and ROTEM instruments using proprietary reagents from each manufacturer...
  34. ncbi request reprint Human platelet osteonectin: release, surface expression, and partial characterization
    R J Kelm
    University of Vermont, College of Medicine, Department of Biochemistry, Burlington 05405
    Blood 75:1105-13. 1990
    ..Collectively, these data suggest that platelet osteonectin is structurally distinct from bone osteonectin in a region of the molecule at a distance from the NH2-terminus...
  35. ncbi request reprint The regulation of clotting factors
    M Kalafatis
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington 05405 0068, USA
    Crit Rev Eukaryot Gene Expr 7:241-80. 1997
    ..abstract..
  36. ncbi request reprint The role of the tissue factor pathway in initiation of coagulation
    K G Mann
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington 05405 0068, USA
    Blood Coagul Fibrinolysis 9:S3-7. 1998
    ..As a consequence of the roles of pro, and anti-coagulants, the generation of thrombin by the TF pathway becomes a threshold limited process...
  37. ncbi request reprint Immunologic quantitation of tissue factors
    B Parhami-Seren
    Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT 05446 0068, USA
    J Thromb Haemost 4:1747-55. 2006
    ..These differential recognition patterns affect TF quantitation in plasma and should be considered when evaluating plasma TF-like antigen concentrations...
  38. ncbi request reprint Peptidomimetic inhibitors for activated protein C: implications for hemophilia management
    S Butenas
    Department of Biochemistry, University of Vermont, Colchester, VT 05446, USA
    J Thromb Haemost 4:2411-6. 2006
    ..Experiments using a synthetic coagulation proteome model showed that the presence of FV Leiden significantly increased thrombin generation in the absence of FVIII or FIX...
  39. ncbi request reprint Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial
    R P Tracy
    Department of Pathology, University of Vermont College of Medicine, Colchester 05446, USA
    Am Heart J 135:29-37. 1998
    ..The aPTT results support frequent monitoring during the first 24 to 48 hours to ensure optimal clinical outcome. The coagulation factor results suggest that there may be an optimum window for fibrinogenolysis in this setting...
  40. ncbi request reprint Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition
    K Brummel-Ziedins
    Department of Biochemistry, University of Vermont, VT 05446, USA
    J Thromb Haemost 6:104-10. 2008
    ..We investigated whether thrombin generation based on circulating coagulation protein levels, could distinguish between acute and stable coronary artery disease (CAD)...
  41. ncbi request reprint Differential effects of anticoagulants on the activation of platelets ex vivo
    D J Schneider
    Department of Medicine, University of Vermont College of Medicine, Burlington 05405, USA
    Circulation 96:2877-83. 1997
    ....
  42. ncbi request reprint Thrombolytic therapy and proteolysis of factor V
    R P Tracy
    Department of Pathology, College of Medicine, University of Vermont, Burlington, USA
    J Am Coll Cardiol 30:716-24. 1997
    ..We sought to determine the extent of Factor V proteolysis during thrombolytic therapy...
  43. pmc Coagulation procofactor activation by factor XIa
    M F Whelihan
    Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT, USA
    J Thromb Haemost 8:1532-9. 2010
    ..FIXa is an extremely poor catalyst in the absence of its FVIIIa cofactor, which, in the intrinsic FXase complex, increases FXa generation by approximately 10(7). One potential APTT procofactor activator in this setting is FXIa...
  44. pmc The influence of von Willebrand factor on factor VIII activity measurements
    S Butenas
    Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT 05446, USA
    J Thromb Haemost 7:132-7. 2009
    ..It has been reported by multiple laboratories that the quantitation of factor (F)VIII by activity-based assays is influenced by the method, procedure and the quality of reagents used in the assays...
  45. ncbi request reprint Thrombosis: theoretical considerations
    K G Mann
    Department of Biochemistry, University of Vermont College of Medicine, Burlington 05405 0068, USA
    Am J Clin Nutr 65:1657S-1664S. 1997
    ....
  46. pmc Discordant fibrin formation in hemophilia
    K E Brummel-Ziedins
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT, USA
    J Thromb Haemost 7:825-32. 2009
    ..The conversion of fibrinogen to fibrin and its crosslinking to form a stable clot are key events in providing effective hemostasis...
  47. pmc Thrombin generation and bleeding in haemophilia A
    K E Brummel-Ziedins
    Department of Biochemistry, University of Vermont, College of Medicine, Colchester, VT 05446, USA
    Haemophilia 15:1118-25. 2009
    ..6 +/- 1.3, 4.7 +/- 0.7 and 5.6 +/- 1.3 min. Our empirical study in CTI-inhibited whole blood shows that the MaxL of thrombin generation appears to correlate with the bleeding phenotype of haemophilia A...
  48. pmc Empirical and theoretical phenotypic discrimination
    K E Brummel-Ziedins
    Department of Biochemistry, University of Vermont, Colchester, VT 05446, USA
    J Thromb Haemost 7:181-6. 2009
    ....
  49. ncbi request reprint Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity
    R A Henriksen
    Department of Biochemistry, University of Vermont, Burlington 05405
    Biochemistry 28:2078-82. 1989
    ..These results and those of other investigators studying mutant trypsins support the conclusion that the catalytic activity of serine proteases is very sensitive to structural alterations in the primary substrate binding pocket...
  50. ncbi request reprint Platelets and phospholipids in tissue factor-initiated thrombin generation
    S Butenas
    University of Vermont, Department of Biochemistry, Burlington 05405-0068, USA
    Thromb Haemost 86:660-7. 2001
    ..5 x 10(8)/ml to 3.1 x 10(8)/ml (4.0+/-0.5 min). The data obtained in both models are consistent with in vivo observations that clinical bleeding is most likely to occur at platelet counts <0.1 x 10(8)/ml...
  51. ncbi request reprint Predicting the pharmacology of thrombin inhibitors
    T E Adams
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, Vermont 05405, USA
    J Thromb Haemost 1:1024-7. 2003
    ..The data suggest that numerical models will be useful in predicting the effectiveness of inhibitors of coagulation...
  52. ncbi request reprint What is all that thrombin for?
    K G Mann
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT 05405, USA
    J Thromb Haemost 1:1504-14. 2003
    ....
  53. ncbi request reprint The function of factor XI in tissue factor-initiated thrombin generation
    S Butenas
    Department of Biochemistry, University of Vermont, 89 Beaumont Avenue, Burlington, VT 05405 0068, USA
    J Thromb Haemost 1:2103-11. 2003
    ..These data indicate that (i) FXI has no effect on thrombin generation at 10 pm TF and physiological concentrations of VKDP; (ii) platelets and plasma FXI are able to compensate for the inhibitory effects of elevated VKDP...
  54. ncbi request reprint The resuscitative fluid you choose may potentiate bleeding
    Kathleen Brummel-Ziedins
    Department of Biochemistry, School of Medicine, University of Vermont, Burlington, Vermont 05405, USA
    J Trauma 61:1350-8. 2006
    ..Little is known about how various resuscitative paradigms affect the coagulation cascade, which is essential to controlling hemorrhagic shock...
  55. ncbi request reprint Influence of bivalirudin on tissue factor-triggered coagulation
    Saulius Butenas
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, Vermont, USA
    Blood Coagul Fibrinolysis 18:407-14. 2007
    ..In conclusion, bivalirudin at pharmacologic concentrations is an efficient inhibitor of thrombin generation, platelet activation and clot formation, which acts not as a modulator but as an 'on-off' switch of blood coagulation...
  56. ncbi request reprint Tissue factor activity in whole blood
    Saulius Butenas
    University of Vermont, Department of Biochemistry, Given Building, 89 Beaumont Ave, Burlington, VT 05405 0068, USA
    Blood 105:2764-70. 2005
    ..Our data indicate that the concentration of physiologically active TF in non-cytokine-stimulated blood from healthy individuals cannot exceed and is probably lower than 20 fM...
  57. ncbi request reprint Thrombin formation
    Kenneth G Mann
    Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Chest 124:4S-10S. 2003
    ..This review provides a brief summary of the evolution of knowledge with respect to present-day concepts of thrombin generation via the tissue factor pathway and its regulation...
  58. ncbi request reprint Tissue factor in thrombosis and hemorrhage
    Saulius Butenas
    Department of Biochemistry, University of Vermont, Colchester, VT 05446, USA
    Surgery 142:S2-14. 2007
    ....
  59. ncbi request reprint The dynamics of thrombin formation
    Kenneth G Mann
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, VT 05405, USA
    Arterioscler Thromb Vasc Biol 23:17-25. 2003
    ....
  60. ncbi request reprint The factor V activation paradox
    Thomas Orfeo
    Department of Biochemistry, University of Vermont, 89 Beaumont Avenue, Burlington, VT 05405 0068, USA
    J Biol Chem 279:19580-91. 2004
    ..Direct activation of factor V by factor Xa at physiologically relevant concentrations does not appear to be a significant contributor to factor Va formation...
  61. ncbi request reprint Factor V: a combination of Dr Jekyll and Mr Hyde
    Kenneth G Mann
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington 05405, USA
    Blood 101:20-30. 2003
  62. ncbi request reprint Mechanism of factor VIIa-dependent coagulation in hemophilia blood
    Saulius Butenas
    College of Medicine, University of Vermont, 89 Beaumont Ave, Burlington, VT 05405 0068, USA
    Blood 99:923-30. 2002
    ..Thus, pharmacologic concentrations of factor VIIa cannot restore normal thrombin generation in hemophilia A and hemophilia B blood in vitro. The efficacy of factor VIIa (10-50 nM) in hemophilia blood is dependent on TF...
  63. ncbi request reprint Identification of the primary structural defect in the dysthrombin thrombin Quick I: substitution of cysteine for arginine-382
    R A Henriksen
    Department of Biochemistry, University of Vermont, Burlington 05405
    Biochemistry 27:9160-5. 1988
    ....
  64. ncbi request reprint Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation
    J H Lawson
    Department of Biochemistry, University of Vermont, Burlington 05405
    J Biol Chem 266:11317-27. 1991
    ....
  65. ncbi request reprint Phenotype and genotype expression in pseudohomozygous factor VLEIDEN : the need for phenotype analysis
    M Kalafatis
    Department of Biochemistry, College of Medicine, University of Vermont, Burlington, USA
    Arterioscler Thromb Vasc Biol 19:336-42. 1999
    ....
  66. doi request reprint Factor XIa and tissue factor activity in patients with coronary artery disease
    Saulius Butenas
    University of Vermont, Department of Biochemistry, Burlington, Vermont, USA
    Thromb Haemost 99:142-9. 2008
    ..59 and 0.39, respectively) and between FXIa and TAT (R(2) = 0.64 and 0.63, respectively). In conclusion, the majority of ACS and CAD-MI patients have circulating FXIa that correlates with markers of coagulation and inflammation...
  67. pmc Intracellular and surface distribution of monocyte tissue factor: application to intersubject variability
    Elena M Egorina
    Department of Biochemistry, Institute of Medical Biology, University of Tromsø, Tromsø, Norway
    Arterioscler Thromb Vasc Biol 25:1493-8. 2005
    ..We characterized patterns of intracellular accumulation, externalization, and shedding of TF in response to LPS in mononuclear cells (MNCs) from high responders (HRs) and low responders (LRs)...
  68. ncbi request reprint The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders
    C van't Veer
    Department of Biochemistry, University of Vermont, Burlington, USA
    Semin Thromb Hemost 26:367-72. 2000
    ..Our data strongly indicate that the therapeutic mechanism of factor VIIa in the medical treatment of hemophiliacs with inhibitors is in large part based on overcoming the inhibitory effect of factor VII on thrombin generation...
  69. ncbi request reprint Homocysteine inhibits inactivation of factor Va by activated protein C
    A Undas
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington, Vermont 05405-0068, USA
    J Biol Chem 276:4389-97. 2001
    ....
  70. ncbi request reprint Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia
    Saulius Butenas
    University of Vermont, College of Medicine, Burlington, VT 05405 0068, USA
    Arterioscler Thromb Vasc Biol 23:123-9. 2003
    ..This study was performed to evaluate the influences of phospholipids and recombinant factor VIIa (rFVIIa) on thrombin generation and clot formation in "acquired" hemophilia B...
  71. pmc Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients
    Anetta Undas
    Arterioscler Thromb Vasc Biol 25:1524-5. 2005
  72. ncbi request reprint A model for the stoichiometric regulation of blood coagulation
    Matthew F Hockin
    Department of Biochemistry, College of Medicine, University of Vermont, Burlington, Vermont 05405, USA
    J Biol Chem 277:18322-33. 2002
    ..A comparison of the model with empirical laboratory data illustrates that most experimentally observable parameters are captured, and the pathology that results in enhanced or deficient thrombin generation is accurately described...
  73. ncbi request reprint Determination of the disulfide bridges in factor Va heavy chain
    J Xue
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington 05405 0068
    Biochemistry 33:13109-16. 1994
    ..Each A domain contains a 26 residue "alpha loop at positions 139-165, 471-497, and 1684-1710. The A1 and A2 domains each contain 81 amino acid residue "beta" loops at 220-301 and 579-660.(ABSTRACT TRUNCATED AT 250 WORDS)..
  74. ncbi request reprint Active tissue factor in blood?
    Saulius Butenas
    Nat Med 10:1155-6; author reply 1156. 2004
  75. ncbi request reprint Factor VII-activating protease: coagulation, fibrinolysis, and atherothrombosis?
    Kenneth G Mann
    Circulation 107:654-5. 2003
  76. pmc Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions
    Anetta Undas
    Institute of Cardiology, Jagiellonian University School of Medicine, Krakow, Poland
    Blood 109:2285-92. 2007
    ..Elucidation of the actual impacts of aspirin other than antiaggregation effects could be important in view of the widespread use of this drug in the prevention of thrombotic manifestations of atherosclerosis...
  77. ncbi request reprint The significance of circulating factor IXa in blood
    Saulius Butenas
    Department of Biochemistry, University of Vermont, Burlington, Vermont 05405 0068, USA
    J Biol Chem 279:22875-82. 2004
    ....
  78. ncbi request reprint A review of the therapeutic uses of thrombin
    Roger L Lundblad
    Department of Pathology, University of North Carolina at Chapel Hill, USA
    Thromb Haemost 91:851-60. 2004
    ..However, the availability of a safe human thrombin preparation will be critical for the continued use of thrombin as a therapeutic...
  79. ncbi request reprint Identification of an inactivating cleavage site for alpha-thrombin on the heavy chain of factor Va
    Evrim Erdogan
    Department of Chemistry, Cleveland State University, 2351 Euclid Avenue, Science and Research Center SR 370, Cleveland, Ohio 44115, USA
    Thromb Haemost 98:998-1006. 2007
    ..Our data demonstrate that cleavage of FVa at Arg(643) by alpha-thrombin results in a partially inactive cofactor molecule and provides for an activated protein C (APC)-independent anticoagulant effect of alpha-thrombin...
  80. ncbi request reprint Cofactor proteins in the assembly and expression of blood clotting enzyme complexes
    K G Mann
    Department of Biochemistry, University of Vermont, Burlington 05405
    Annu Rev Biochem 57:915-56. 1988
  81. ncbi request reprint Structure of human osteonectin based upon analysis of cDNA and genomic sequences
    X C Villarreal
    Department of Biochemistry, University of Vermont, Burlington 05405
    Biochemistry 28:6483-91. 1989
    ..Intron/exon junction sequencing of the human osteonectin gene shows the presence of 10 exons and 9 introns. The mature protein is encoded by nine exons separated by eight introns.(ABSTRACT TRUNCATED AT 250 WORDS)..
  82. pmc The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function
    Ty E Adams
    Department of Biochemistry, College of Medicine, University of Vermont, 89 Beaumont Avenue, Burlington, VT 05405, USA
    Proc Natl Acad Sci U S A 101:8918-23. 2004
    ..This structure represents the largest physiologically relevant fragment of factor Va solved to date and provides a new scaffold for the future generation of models of coagulation cofactors...
  83. ncbi request reprint A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa
    Richard J Jenny
    Haematologic Technologies, Inc, Essex Junction, VT, USA
    Protein Expr Purif 31:1-11. 2003
    ..Examples are presented which describe the proteolysis of the protein of interest by either factor Xa or thrombin...
  84. ncbi request reprint Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism
    Anetta Undas
    Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland
    Circulation 107:17-20. 2003
    ....

Research Grants22

  1. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 1999
    ..abstract_text> ..
  2. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2004
    ..The major aim of this project is to elucidate the structure/function relationships of this material with respect to factor V inactivation and to access its potential significance in the pathology of human thrombosis. ..
  3. Symphony Multiplex Peptide Synthesizer w/ VISION Workstn
    Kenneth Mann; Fiscal Year: 2004
    ..The principle investigator, Dr. Kenneth Mann and co-principle investigator Dr...
  4. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2005
    ..The major aim of this project is to elucidate the structure/function relationships of this material with respect to factor V inactivation and to access its potential significance in the pathology of human thrombosis. ..
  5. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2006
    ..The major aim of this project is to elucidate the structure/function relationships of this material with respect to factor V inactivation and to access its potential significance in the pathology of human thrombosis. ..
  6. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2007
    ..The major aim of this project is to elucidate the structure/function relationships of this material with respect to factor V inactivation and to access its potential significance in the pathology of human thrombosis. ..
  7. HEMOSTASIS AND THROMBOSIS PROGRAM FOR ACADEMIC TRAINEES
    Kenneth Mann; Fiscal Year: 2007
    ..Trainees are therefore well prepared for future research endeavors in any field. (End of Abstract) ..
  8. Surface Dependent Reactions in Thrombosis and Thrombolysis
    Kenneth Mann; Fiscal Year: 2007
    ..abstract_text> ..
  9. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2003
    ..abstract_text> ..
  10. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2002
    ..abstract_text> ..
  11. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2000
    ..abstract_text> ..
  12. PE BIOSYSTEMS VOYAGER DE MALDI-TOF
    Kenneth Mann; Fiscal Year: 2001
    ..The fulfillment of the specific aims described in detail in the twelve research proposals would be facilitated by the addiction of a Voyager-DE MALDI-TOF ..
  13. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2001
    ..abstract_text> ..